– NORWAY, Oslo – PHARMAQ, in an extraordinary shareholders meeting today, has elected Mr. George Gunn as a board member in Pharmaq Holding AS. Mr. Gunn has extensive competence and experience from the animal health sector, latest as Division Head, Novartis Animal Health until completion of the sale of the division to Elanco in 2015. The board of Pharmaq Holding AS will as a result of the election of George Gunn be increased from six to seven members.
George Gunn recently retired from Novartis AG where he had been a member of the Executive Committee since 2008. He joined Novartis in 2003 as Head of Animal Health, North America and moved on to head Novartis Animal Health from 2004. He went on to be head of the Novartis Consumer Health Division and also managed the Corporate Social Responsibility area for the Novartis Corporation.
Mr. Gunn is a native of the Shetland Islands (Scotland) and he has spent more than 30 years in Healthcare Industry. Prior to joining Novartis, he spent 3 years as President of Pharmacia Animal Health, Pharmacia Corporation’s global animal health business based in Kalamazoo, Michigan USA. Mr. Gunn began his career with Johnson & Johnson in 1986 and held several positions until he moved to Pharmacia in 2000.
Mr. Gunn holds the degree of Bachelor of Veterinary Medicine and Surgery and a Post Graduate Diploma in Veterinary State Medicine, both from the Royal Dick School of Veterinary Studies in Edinburgh. In 2008 Mr. Gunn received the Honorary Degree of Doctor of Veterinary Medicine and Surgery from theUniversityofEdinburgh.
Throughout his career Mr. Gunn has held leadership positions in industry associations and received several awards. Latest, in 2015 he received a Lifetime Achievement award from the International Federation of Animal Health for his services to Animal Health Industry.
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.